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hazard ratio (HR) 3.2, 95% confidence interval (CI) 1.5-6.6) and detection of tumoral hemorrhage (p=
0.008, HR 2.5, 95% CI 1.3-4.9). Pre-operative seizures occurred predominantly in patients with supraten-
torial BM (p=0.003, HR 20.78, 95% CI 2.8-153.4) and lung cancer (p= 0.022; HR 2.0, 95% CI 1.1-3.6).
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24.3), incomplete resection (p=0.005, HR 4.6, 95% CI 1.6-13.1), and by trend for multiple brain surgeries
(p=0.095, HR 1.9, 95%CI 0.9-4.0). These risk factors were integrated into a predictive score model for
post-operative epilepsy (score sum 0-8). A gradual increase of seizure rates along with higher sum score
was confirmed post-hoc (score 0, no seizures; score 8, 48% seizures). Receiver-operating characteristic
analysis supported diagnostic accuracy (p=0.00001, AUC=0.75). CONCLUSIONS Here we have defined
risk profiles for the development of BM-related epilepsy and derived a score which might help to esti-
mate the risk of post-operative seizures and identify individuals at risk who might benefit from primary
prophylactic anti-epileptic drug therapy.
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Abstract 1 
BACKGROUND: Current guidelines do not recommend primary prophylactic anti-2 
epileptic drug therapy for patients with brain metastases (BM). Yet, subgroups of 3 
patients at high seizure risk might still benefit from prophylaxis. 4 
METHODS: We identified 799 patients diagnosed with BM by retrospective 5 
screening of our electronic chart system. Candidate risk factors for the development 6 
of epilepsy were tested by univariate and multivariate Cox regression models. 7 
RESULTS: Epilepsy was diagnosed in 226 of 799 patients (28%). Risk factors for 8 
epilepsy in non-operated patients were single BM (p=0.002, hazard ratio (HR) 3.2, 9 
95% confidence interval (CI) 1.5-6.6) and detection of tumoral hemorrhage (p= 10 
0.008, HR 2.5, 95% CI 1.3-4.9). Pre-operative seizures occurred predominantly in 11 
patients with supratentorial BM (p=0.003, HR 20.78, 95% CI 2.8-153.4) and lung 12 
cancer (p= 0.022; HR 2.0, 95% CI 1.1-3.6). Post-operative seizures were associated 13 
with supratentorial localization (p=0.017, HR 5.8, 95% CI 1.4-24.3), incomplete 14 
resection (p=0.005, HR 4.6, 95% CI 1.6-13.1), and by trend for multiple brain 15 
surgeries (p=0.095, HR 1.9, 95%CI 0.9-4.0). These risk factors were integrated into 16 
a predictive score model for post-operative epilepsy (score sum 0-8). A gradual 17 
increase of seizure rates along with higher sum score was confirmed post-hoc (score 18 
0, no seizures; score 8, 48% seizures). Receiver-operating characteristic analysis 19 
supported diagnostic accuracy (p=0.00001, AUC=0.75). 20 
CONCLUSIONS: Here we have defined risk profiles for the development of BM-21 
related epilepsy and derived a score which might help to estimate the risk of post-22 
operative seizures and identify individuals at risk who might benefit from primary 23 
prophylactic anti-epileptic drug therapy. 24 
 25 
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Key points 1 
• Epilepsy was diagnosed in 226 of 799 patients (28%) with brain metastasis 2 
(BM) 3 
• Post-operative seizures were associated with supratentorial BM, residual 4 
tumor or repeat brain surgery 5 
• A predictive model for seizures was derived from patients` risk profiles 6 
 7 
Importance of the study 8 
Brain tumor-related epilepsy is a frequent and clinically highly relevant complication 9 
of brain metastasis. However, current guidelines do not recommend primary 10 
prophylactic antiepileptic drug (AED) treatment for seizure-free patients with brain 11 
metastasis since no benefit from general prophylaxis has been demonstrated so far. 12 
Furthermore, AED treatment may have significant side effects, interfere with 13 
systemic cancer therapy, and generates addditional cost. Conversely, seizure 14 
prevention is of high clinical importance since seizures negatively impact quality of 15 
life, for patients and for caregivers, and possibly outcome, too. In clinical practice, 16 
AED treatment is started following a first seizure, or based on an individual decision 17 
of the treating physician. Here we provide risk profiles for the development of 18 
seizures in patients with and without tumor resection. We have developed a 19 
predictive score to support clinicians in the identification of patients at high risk for 20 
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Introduction 1 
Brain tumor-related epilepsy (BTRE) is common in patients with brain metastases 2 
(BM) from systemic tumors and thought to contribute to morbidity and mortality 1,2. 3 
Freedom from seizures is essential for favorable quality of life in brain tumor patients 4 
3-5. BTRE life-time risk in BM patients is estimated at 20-35% to 67% 6-8. Diagnosis of 5 
BTRE commonly necessitates the initiation of secondary prophylaxis whereas 6 
primary prophylactic AED treatment in response to a BM diagnosis is not indicated 9. 7 
This is because several retrospective studies have failed to demonstrate a general 8 
risk reduction for developing BTRE with primary prophylaxis 10-12. However, 9 
subgroups of patients with high risk of seizures might still benefit from primary 10 
prophylaxis 13.  11 
There are only limited data to estimate the risk of developing BTRE in BM patients, 12 
mostly from retrospective studies of patient cohorts that also include patients with 13 
primary brain tumors 7,14 or patients with distinct tumor entities, e.g. melanoma 13.  14 
Although available data and current guidelines 9 do not support the concept of 15 
primary prophylaxis with AED, although these are nevertheless often prescribed in 16 
BM patients without BTRE, e.g., prior to BM resection or on an individual base if the 17 
patient is thought to be at increased seizure risk. Possible seizure prevention has to 18 
be weighed against risk of drug interactions and of relevant side effects associated 19 
with AED therapy. This is particularly true for older AED like phenytoin or 20 
phenobarbital 15. 21 
A better understanding of risk factors for BTRE might help to define a role for primary 22 
prophylactic AED therapy in subgroups of BM patients. Gross total resection, 23 
radiotherapy and chemotherapy are thought to contribute to seizure control in glioma 24 
patients 7,8,17. Conversely, pre- or post-operative hemorrhage and multiple lesions 25 
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were associated with increased seizure risk in BM patients 13 and detection of 1 
cortical hemosiderin correlated with seizure risk in a retrospective study including 36 2 
BM patients 14.  3 
The major goal of this study was to define subgroups of BM patients at high risk for 4 
BTRE that might benefit from primary AED therapy. To this end, we retrospectively 5 
studied a clinically well-annotated cohort of 811 patients with BM. Since surgery can 6 
either contribute to improved seizure control following resection or can in turn result 7 
in post-operative onset of new seizures, separate analyses for pre-operative BTRE, 8 
post-operative BTRE, and BTRE in non-operated patients were conducted, with the 9 
intent to build risk prediction models for BTRE in BM patients. 10 
 11 
  12 
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Materials and methods 1 
 2 
Patients 3 
We screened the electronic chart system of the University Hospital Zurich for 4 
patients diagnosed with BM between January 2004 and December 2014, employing 5 
the search term “brain metastasis”. Of 843 adult patients, 13 patients were excluded 6 
because of missing informed consent and 19 patients because of alternative 7 
diagnoses. Of the remaining 811 patients, 568 patients had a brain biopsy or 8 
resection. Follow-up data until death were available for 628 patients (77%) whereas 9 
183 patients (23%) were followed up for a median of 17.0 months (95% CI 12.0-23.0 10 
months). This study was approved by the Cantonal Ethics Committee Zurich (KEK-11 
ZH-Nr. 2018-00192). 12 
 13 
Assessments 14 
At least one unprovoked seizure in a patient with a diagnosis of BM was defined as 15 
BTRE according to the criteria of the International League Against Epilepsy (ILAE) 16 
that were valid when data were collected 18. A new classification of seizures have 17 
been established meanwhile 19. Post-operative epilepsy was diagnosed in patients 18 
with documented epileptic seizures during post-operative follow-up, except for 19 
seizures within 7 days of craniotomy. The latter are referred to as acute symptomatic 20 
post-operative and thus provoked seizures 20. All patients with provoked seizures 21 
only were assigned to the non-BTRE group. 22 
Patient characteristics, histopathological data and clinical data including neurological 23 
deficits, seizure history, post-operative course, complications and medication were 24 
obtained by electronic chart reviews. Reports of cranial computed tomography (CT) 25 
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and magnetic resonance imaging (MRI) scans were reviewed to assess number, 1 
localization and morphology of BM and to define presence of tumoral hemorrhage, 2 
tumor progression and extent of resection. Absence of contrast-enhancing tumor on 3 
post-operative MRI scans was rated as gross total resection. 4 
 5 
Statistical methods 6 
Analysis of nominal variables was performed employing the Chi-square test, analysis 7 
of linearly scaled variables was done with the Mann-Whitney U test. Significant 8 
differences of paired nominal data were assessed employing McNemar’s test. 9 
Differences between ordinally coded data in unpaired samples were assessed by the 10 
Kruskal-Wallis test. Binary logistic regression analysis was performed to assess for 11 
factors independently associated with pre-operative seizures. Variables which were 12 
associated with BTRE in univariate analyses were carried forward for multivariate 13 
testing using a Cox regression model including post-operative follow-up for seizures 14 
and seizure occurrence. Other variables previously reported to be associated with 15 
seizures were included in our model as possible confounders. Multivariate models 16 
for BTRE were derived separately for operated and non-operated patients, based on 17 
results from univariate analysis. We integrated the results in a predictive score 18 
model. Score values were derived from respective hazard ratios (HR) for each item 19 
and confirmed using beta-coefficient values of regression. Receiver-operating 20 
characteristic (ROC) curves were used to rate score validity. An area under the 21 
curve (AUC) of 0.5 reflects no discrimination between risk groups, an AUC of 1 a 22 
perfect discrimination between subjects at high and low risk, and an AUC>0.7 is 23 
widely accepted as cut-off for clinically relevant discrimination capacity of a clinical 24 
score 21. 25 
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Statistical analysis was performed by IBM SPSS statistics ®, Version 23 (IBM Co., 1 
Armonk, NY, USA) and GraphPad Prism software, version 7.0 (La Jolla, CA, USA). 2 
For two-sided p-values, results with p<0.05 were considered significant and with 3 
p<0.01 highly significant. 4 
 5 
Data availability statement 6 
The data that support the findings of this study are available from the corresponding 7 
author, upon reasonable request (fabian.wolpert@usz.ch). 8 
  9 
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Results 1 
 2 
Patient characteristics 3 
Interrogation of the electronic database allowed the identification of 811 BM patients. 4 
Twelve patients were excluded because of a history of prior epilepsy (Figure 1, 5 
CONSORT chart). Of the final cohort of 799 patients, 237 patients (30%) had at least 6 
one documented seizure. In five patients, a provocation factor, e.g., more than 7 
moderate alcohol consumption, alcohol withdrawal, low serum sodium levels or 8 
infection, was reported, two of these five patients later suffered from at least one 9 
unprovoked seizure and then fulfilled ILAE criteria for BTRE. Ten patients had a 10 
seizure within the first week after surgery which were rated as provoked by surgery 11 
18. Two of these patients had at least one or more unprovoked seizures in the further 12 
course of disease and were therefore included in the BTRE group. Altogether, 226 of 13 
799 patients (28%) had at least one unprovoked epileptic seizure and thus fulfilled 14 
BTRE criteria (Table 1). Seizure rates varied from one up to 13 seizures (Figure 2A). 15 
There was no association between the first clinical symptom of BM and BTRE 16 
(Figure 2B). Most seizures occurred within one week from diagnosis of BM whereas 17 
other seizures occurred preferentially in the later course of disease beyond 12 18 
weeks, potentially indicative of progressive disease (Figure 2C). In operated patients 19 
the majority of the first and second seizures occurred before surgery whereas few 20 
seizures occurred within the first 12 weeks after surgery (Figure 2D), consistent with 21 
surgery-afforded seizure control. 22 
To further assess the role of tumor progression for BTRE in patients with known 23 
brain metastasis, we evaluated imaging results obtained within one week of the first 24 
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seizure. This information was available for 76 previously seizure-free patients. Tumor 1 
progression was noted in 47 of these patients (62%). 2 
 3 
AED use in BTRE 4 
AED treatment was assessed before and after the time of occurrence of a first 5 
seizure as well as one year after the diagnosis of BM. Information on AED 6 
prophylaxis after diagnosis of BM and prior to any documented seizure was available 7 
for 796 patients (Table S1). BTRE risk did not differ between patients with (31%) 8 
versus without primary prophylaxis (31%) (Table 1). Justification of primary 9 
prophylaxis was documented for 138 of 153 patients: individual decisions of treating 10 
clinicians (52 patients, 38%), pathologic EEG findings (30 patients, 22%), 11 
continuation of peri-operative prophylaxis (52 patients, 38%), other reasons like 12 
treatment of neuropathic pain (4 patients, 3%). Information on AED prophylaxis was 13 
available for 554 of 557 operated patients, in 115 of those BTRE was diagnosed 14 
before surgery. In the remaining patients, BTRE was diagnosed in 14 of 236 patients 15 
(5.9%) with no AED prophylaxis, in 32 of 138 patients (23.2%) with primary 16 
prophylaxis and 1 of 65 patients (1.5%) with peri-operative prophylaxis which was 17 
started prior to and stopped within 4 weeks after surgery (p=0.0005). 18 
 19 
Seizure types 20 
There was a trend towards association of generalized non-convulsive seizures with 21 
lower median KPS (p=0.053) and with higher number of BM (p=0.073, Kruskal-Wallis 22 
test). There was no association of seizure type and gender (p=0.187), extent of 23 
resection (p=0.121), initial symptom (p=0.405), lobe (p=0.312), hemisphere 24 
(p=0.593) or detection of intracranial hemorrhage (p=0.555) (Chi-square test). Focal 25 
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seizures with retained awareness were more common in operated patients (75 of 1 
182 patients, 41.2% versus 10 of 47 patients, 21.3% in non-operated patients) 2 
whereas focal seizures with impaired awareness occurred more frequently in non-3 
operated patients (11 of 47 patients, 23.4% versus 11 of 182 patients, 6.0%, in 4 
operated patients; p=0.002) (Chi-square test). 5 
 6 
Risk factors for BTRE in non-operated patients 7 
Characteristics of 242 patients, who were not operated, are shown in Table S2; 49 8 
patients (20.2%) had BTRE. BTRE was associated with number of BM (p=0.013, 9 
Mann-Whitney U test) and more common in patients with one BM (17 of 51 patients, 10 
33.3%) than in patients with multiple BM (31 of 189 patients, 16.5%; p=0.007, Chi-11 
square test). Patients with a single cortical supratentorial BM, defined as less than 12 
one cm distance from the cortex, or subcortical BM, defined as 1-2 cm from the 13 
cortex, showed no difference in BTRE rate, compared with BM in the deep white 14 
matter (> 2 cm from the cortex; Table S2). There was no association of BTRE with 15 
histology of the primary tumor (p=0.816), chemotherapy after diagnosis of BM 16 
(p=0.911, data not shown) or steroid intake at any time during the clinical course 17 
(p=0.977, data not shown, all Chi-square test). Supratentorial versus infratentorial 18 
tumor location of a single BM was not associated with BTRE either. This difference 19 
was still not significant for early occurrence of BTRE (< 12 weeks; supratentorial: 6 of 20 
24 patients (25.0%) compared to infratentorial: 1 of 9 patients (11.1%), p=0.360). 21 
Hemorrhagic transformation of the tumor was found upon initial imaging in more than 22 
a third of the patients, with the highest rate in melanoma. Detection of tumoral 23 
hemorrhage was associated with the diagnosis of BTRE (p=0.021). We used a Cox 24 
regression model with time to first seizure as an outcome measure for multivariate 25 
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testing to exclude bias from diverging survival. Both single BM (p=0.002, HR 3.2, 1 
95% CI 1.5-6.6) and detection of tumoral hemorrhage (p=0.008, HR 2.5, 95% CI 1.3-2 
4.9) were retained as independent factors associated with BTRE. Post-hoc 3 
calculation revealed BTRE in 13 of 116 patients (11.2%) with none, in 27 of 106 4 
patients (25.5%) with one and in 7 of 14 patients (50%) with both risk factors, single 5 
BM and tumoral hemorrhage. 6 
 7 
Risk factors for pre-operative seizures 8 
Information on pre-operative seizures was available for 554 of 557 operated patients. 9 
They were reported in 112 of these patients (19.2%) and were the first symptom of 10 
BM in 62 of these patients (11.2%). There was no association between pre-operative 11 
BTRE and the number of metastases (p=0.433), KPS (p=0.319), age (p=0.160, 12 
Table S3), or steroid use (p=0.187, not shown) or initial symptom (p=0.572, both Chi-13 
square test). However, there was an association between primary tumor histology 14 
and pre-operative seizures (p=0.037): we noted an increased incidence of pre-15 
operative seizures in patients with lung cancer (p=0.007) and a decreased incidence 16 
of pre-operative seizures in patients with breast cancer (p=0.005). Furthermore, 17 
patients with a single cortical or sub-cortical supratentorial BM showed a trend 18 
towards increased seizure risk compared to deep-seated BM (p=0.075). The largest 19 
fraction of patients with pre-operative seizures had frontal BM (33.7%, p=0.007), 20 
followed by parietal single BM (24.4%, p=0.911), occipital (16.0%, p=0.297) and 21 
temporal (6.1%, p=0.11) single BM (Table S3). 22 
Supratentorial versus infratentorial localization was the key risk factor for pre-23 
operative seizures on multivariate analysis (p=0.003, HR 20.78, 95% CI 2.8-153.4), 24 
followed by lung cancer as the primary tumor (p=0.022, HR 2.0, 95% CI 1.1-3.6). A 25 
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sub-analysis for supratentorial tumors revealed localization in the frontal lobe 1 
(p=0.001, HR 2.78, 95% CI 1.5-5.2) as an independent risk factor. 2 
 3 
Risk factors for postoperative seizures 4 
The associations of clinical disease characteristics with post-operative BTRE are 5 
summarized in Table 2. Supratentorial versus infratentorial (p=0.012), or occipital  6 
versus other locations (p=0.027) were associated with post-operative seizures. 7 
Furthermore, single versus more than one brain surgery in the disease course 8 
(p=0.00001), and cerebral venous thrombosis (p=0.030) were associated with post-9 
operative BTRE. BTRE was less common in patients following gross total resection 10 
versus incomplete resection (p=0.008). The development of post-operative BTRE 11 
was associated with brain irradiation (p=0.013, Table 1) as well as chemotherapy 12 
(p=0.002, Table 1). 13 
We then assessed the occurrence of seizures before and after surgery. Altogether, 14 
there was no significant association between pre- and post-operative seizure 15 
occurrence (p=0.077, McNemar test). There was also no significant association of 16 
pre- with postoperative seizures in the subgroup of 197 patients with only single 17 
supratentorial metastasis, with a median follow-up of 6 months (95% CI 6.0-8.0 18 
months) (Figure 3). 19 
Next, we evaluated the association of extent of resection determined by post-20 
operative imaging obtained within one week with postoperative BTRE in patients with 21 
single supratentorial BM. Risk of postoperative seizures was significantly higher after 22 
biopsy or partial resection than after gross total resection (p=0.008) (Table 2). 23 
We then focused on patients with single supratentorial BM who had been seizure-24 
free prior to surgery and explored an association of new BTRE with extent of 25 
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resection. Twenty of 66 patients (30.3%) who had a biopsy or partial resection 1 
developed post-operative BTRE, compared with only 2 of 38 patients (5.3%) with 2 
gross total resection (p=0.003, Chi-square test). In contrast to pre-operative seizures 3 
that were associated with frontal localization of single BM, new diagnosis of BTRE 4 
after surgery was associated with occipital tumor localization (p=0.027, Table 2). In 5 
contrast to pre-operative seizures, tumor histology was not associated with post-6 
operative seizures (p=0.479). 7 
Factors that were associated with post-operative seizures in univariate analysis were 8 
then tested in multivariate analysis, using a Cox regression model. Median post-9 
operative follow-up for seizures was 6.0 months (95% CI 6.0-8.0). Supratentorial 10 
location (p=0.017, HR 5.8, 95% CI 1.4-24.3) and incomplete resection (p=0.005, HR 11 
4.6, 95% CI 1.6-13.1) were independently associated with post-operative seizures, 12 
multiple surgeries (p=0.095, HR 1.9, 95% CI 0.9-4.0) were associated with increased 13 
rate of post-operative seizures by trend (Figure 4A). 14 
 15 
Score models for prediction of post-operative seizures 16 
Finally we integrated the factors associated with post-operative seizures into a model 17 
where supratentorial localization accounts for a score value of four, incomplete 18 
resection for a score of three and multiple surgeries for a score of one, based on HR 19 
values from multivariate analysis. ROC analysis supported the diagnostic accuracy 20 
of the score (p=0.000014, AUC=0.75, 95% CI 0.66-0.84) (Figure 4B). Post-hoc 21 
calculation of this score revealed a gradual increase in seizure frequency (Figure 22 
4C). 23 
24 
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Discussion 1 
 2 
Although BTRE is a common complication in patients with BM, no general benefit 3 
from primary AED prophylaxis in BM patients has been demonstrated 9. However, 4 
subgroups of BM patients might be at higher risk for BTRE and therefore benefit 5 
from primary prophylactic AED treatment, e.g., patients with BM from melanoma 13. 6 
Here we define the risk profile for BTRE in a single institution cohort of 799 BM 7 
patients to identify subgroups of patients at increased risk of BTRE. We report a 8 
BTRE rate of 28%. The BTRE rate was lower in non-operated BM patients (20%) 9 
than in operated patients (32%) (Table 1). These data need to be interpreted with 10 
caution since the decision for surgery was likely often biased, e.g., to achieve 11 
seizure freedom or relief from intracranial pressure. Yet, because of this difference in 12 
BTRE frequency, we defined separate risk profiles for operated and non-operated 13 
patients. Since surgery has been reported to contribute to seizure control in patients 14 
with lower grade gliomas 22, we also decided to define separately the risk profile for 15 
pre-operative versus post-operative seizures. Non-operated patients with single BM 16 
had a higher BTRE rate than patients with multiple BM (Table S2). This finding was 17 
unexpected since a higher tumor burden should result in increased seizure risk. Yet, 18 
BM in potentially epileptogenic regions like the precentral gyrus or mesiotemporal 19 
region might often be difficult to resect. This would result in a selection bias towards 20 
non-operated patients with single lesions in highly epileptogenic regions whereas 21 
surgery is in general less frequently performed in patients with multiple BM, notable 22 
multiple small BM. We furthermore found an increased BTRE rate in non-operated 23 
patients with hemorrhagic lesions (p=0.021) 14, but no other clinical factors 24 
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considered to be potentially associated with BTRE, including depth of BM location, 1 
histology of the primary tumor, type of cancer treatment, or steroid intake. 2 
In operated patients, supratentorial versus infratentorial localization was the key 3 
factor associated with pre-operative seizures on multivariate analysis (p=0.003, HR 4 
20.8), followed by lung cancer as a primary tumor (p=0.022, HR 2.0). We next 5 
performed a subgroup analysis for patients with supratentorial tumors. Here, frontal 6 
localization was a risk factor for pre-operative seizures (p=0.001, HR 2.78). Primary 7 
AED prophylaxis was not associated with BTRE (p=0.582), however, patients who 8 
received peri-operative AED prophylaxis showed a significantly lower BTRE rate 9 
(p=0.0005). However, the latter finding has to be regarded with caution, since 10 
decisions for or against primary or peri-operative AED prophylaxis did not follow an 11 
algorithm, but were made on an individual basis. 12 
A contribution of surgery to improved seizure control in BM patients with pre-13 
operative BTRE is assumed, but remains unproven. We found no significant post-14 
operative decrease of seizure rates in patients with pre-operative seizures, and 15 
inversely no increased rate of new seizures after surgery (Figure 3). However, 16 
seizure freedom is not the primary goal of BM surgery, and neurosurgical 17 
interventions are probably not planned accordingly. Epilepsy surgery with intra-18 
operative EEG mapping for BM patients might be an interesting concept for 19 
individuals refractory to AED treatment. 20 
When defining the risk profile for post-operative seizures, supratentorial versus 21 
infratentorial localization of a single metastasis was again a very strong predictor of 22 
new post-operative BTRE. We thus refined the seizure risk profile of supratentorial 23 
tumors. Univariate testing revealed incomplete resection (p=0.008), multiple 24 
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surgeries (p=0.0003) and occipital (p=0.027) localization, but not tumor histology 1 
(p=0.479) (Table 2) as possible predictors of higher seizure risk.  2 
On multivariate analysis supratentorial localization (p=0.017, HR 5.8), incomplete 3 
resection (p=0.005, HR 4.6) and, by trend, multiple surgeries (p=0.095, HR 1.9) were 4 
retained as independent factors that were associated with post-operative seizures. 5 
Our findings confirm and extend those from another recent cohort study 8. Here, 6 
headache, cognitive deficits, multiple BM, and localization in the temporal or occipital 7 
lobe were reported as risk factors for pre-operative seizures, whereas absence of 8 
frontal lobe involvement and tumor size (diameter > 5 cm) were associated with poor 9 
pre-operative seizure control. We also found a lower frequency of post-operative 10 
seizures in patients with frontal BM, but no association with cognitive deficits or 11 
headache as first symptom from BM (Figure 2). Furthermore, we found no 12 
association between pre-operative seizures and the number of BM (Table S3). We 13 
confirm incomplete resection as a strong predictor of post-operative seizures 8. In 14 
fact, we speculate that differential extent of resection may contribute to the relative 15 
association of post-operative BTRE with occipital rather than frontal BM location in 16 
our cohort. Alternatively, or in addition, there may be detection bias in pre-operative 17 
patients where motor seizures from frontal areas are more often recognized as such 18 
than more subtle seizure types, with occipital or parietal lesions. BM in the latter 19 
location may be more often diagnosed because of focal neuro(psycho)logical 20 
deficits. 21 
The retrospective character of our cohort study is its major limitation. There was a 22 
possible bias on under-reporting of seizures. Sample sizes for some subgroup 23 
analyses were small. Causal links between BM and seizures are commonly 24 
considered compelling, but other seizure etiologies including metabolic disturbances 25 
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and side effects from cancer therapies are difficult to rule out, notably in a 1 
retrospective setting, and in this specific patient population.  2 
A major strength is the overall large sample size which allowed us to define risk 3 
factors across treatment modalities or primary tumor entities. This contrasts with 4 
previous cohort studies or controlled trials that were e.g. restricted to tumor entities 5 
13, single treatment modalities like neurosurgery 8,11 or included patients with primary 6 
brain tumors 7,14. The size of our cohort allowed us also to perform some subgroup 7 
analyses and assess risk factors for seizures in different clinical settings, namely 8 
non-operated patients and operated individuals in the pre- and post-operative phase. 9 
We finally developed a score model, by which groups with diverging post-operative 10 
seizure risk can be identified, ranging from 0% to almost 50%. 11 
Although our score model is based on a retrospective analysis from a single center, 12 
it might provide a valuable clinical tool for clinical decision making. Patients who are 13 
not operated might not benefit from primary prophylaxis because of their low seizure 14 
risk, except for the subgroup with single and hemorrhagically transformed BM which 15 
showed a seizure rate of about 50%. Patients who are planned for surgery of a 16 
single supratentorial BM are candidates for peri-operative prophylaxis, which might 17 
be considered to be maintained in patients with incomplete resection of 18 
supratentorial single BM. Further validation in independent cohorts and ideally in 19 
prospective controlled trials is required to refine the outlined predictive model and to 20 
further improve its prognostic accuracy. 21 
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Figure legends 1 
 2 
Figure 1: CONSORT chart. The consort chart shows the selection path for patients 3 
to be included this study. The upper part documents the preselection process to 4 
identify all BM patients and exclude patients with missing consent or alternative 5 
diagnosis. Next, patients with prior diagnosis of epilepsy were excluded from further 6 
assessment. The lower part shows separation of patients who underwent 7 
neurosurgery or no surgery. Pre- and post-operative BTRE risk profiles were 8 
assessed in separate. 9 
 10 
Figure 2. Seizure characteristics in BM patients with BTRE. A. The documented 11 
numbers of seizures per number of patients are shown as bar plots. B. Stacked bar 12 
plots showing initial symptoms of patients with (grey) or without (black) seizures. 13 
Patients with a seizure as the first symptom of BM are excluded here. C,D. The 14 
occurrence of the first five seizures per number of patients over time is shown from 15 
the diagnosis of BM (C) or from surgery (D) as grouped bar plots. 16 
 17 
Figure 3. Pre- and post-operative seizures in operated patients. 18 
Schematic presentation of pre- and post-operative seizures in patients with a single 19 
superatentorial BM. Bold arrows indicate patients who had no diagnosis of BTRE 20 
and remained seizure free after surgery (upper bold arrow) or had a diagnosis of 21 
BTRE and ongoing seizures following surgery (lower bold arrow). Thin arrows 22 
indicate patients who were so far seizure free and develop post-operative BTRE 23 
(upper, down-going thin arrow) or patients with BTRE who become seizure free after 24 
surgery (lower up-going thin arrow). P-value as indicated (McNemar’s test). 25 
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 1 
Figure 4. Predictive score model for post-operative BTRE. A. Results of 2 
multivariate testing are shown as a small table depicting risk factors, HR values with 3 
95% CI and two-sided p-values. B. The ROC curve is shown for the predictive score 4 
model (dashed black line). AUC and p values as well as the 95% CI are indicated. C. 5 
The score sums and number of patients are shown as stacked bar plots. The black 6 
part of each bar represents the fraction of seizure-free patients, the grey part those 7 
with seizures. Percentages are indicated above each bar. 8 
 9 
  10 
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Incomplete resection (y/n) 4.6 (1.6-13.1) 0.005
Supratentorial localization (y/n) 5.8 (1.4-24.3) 0.017
Multiple surgeries (y/n) 1.9 (0.9-4.0) 0.095
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Abstract 1 
PURPOSE: Overweight may be associated with favorable outcome whereas tumor 2 
cachexia may be associated with worse outcome in patients with metastatic cancer. 3 
Here we evaluate the association of abnormal body mass index and weight change 4 
with outcome in patients with brain metastasis. 5 
METHODS: Patients with a diagnosis of brain metastasis treated at the University 6 
Hospital Zurich (n=703) were assessed for associations of body mass index, weight 7 
change, comorbidities and survival. 8 
RESULTS: Compared with patients with normal body mass index of 18.5-24.9 kg/m2 9 
and a median overall survival of 9 months (95% confidence interval 7.5-10.5), overall 10 
survival was inferior in patients with body mass index<18.5 kg/m2 (overall survival 6 11 
months, 95% confidence interval 1.6-10.3, p=0.04), but superior in patients with body 12 
mass index>25 kg/m2 (overall survival 13 months, 95% confidence interval 11.0-15.0; 13 
p=0.033). We report a median relative weight loss of 5% within the first 6 months of 14 
diagnosis of brain metastasis (95% confidence interval 3.3-6.5), and reduction 15 
exceeding the median was associated with an unfavorable outcome (weight loss 16 
<5% 22.0 months, 95% confidence interval 19.2-24.8; weight loss >5% 14.0 months, 17 
95% confidence interval 11.9-16.). 18 
CONCLUSION: High body mass index is associated with better, and underweight 19 
with worse outcome in patients with brain metastasis. Conversely, weight loss above 20 
median may predict poor outcome. Future studies need to address whether vigorous 21 
treatment of tumor cachexia, e.g. by specific nutrition management, might improve 22 
outcome of patients with brain metastasis. In contrast, regimens associated with 23 
weight loss such as ketogenic diet may be detrimental. 24 
Keywords: cachexia; denutrition; BMI; cerebral; prognosis  25 
Page 5 of 22 
1. Introduction 1 
Approximately one fourth of all cancer patients develop brain metastases during their 2 
course of disease [1, 2]. Factors associated with favorable outcome in these patients 3 
include low number of brain metastases, young age, high Karnofsky performance 4 
score (KPS), absence of extracranial metastases and controlled primary tumor [1, 3]. 5 
Several reports have described a superior outcome of obese patients in different 6 
tumor entities including lung, gastric or colorectal cancer [4-7] at different disease 7 
stages, also referred to as the obesity paradox in cancer. Obese patients with distant 8 
metastases from various tumors were recently reported to have better survival than 9 
normal weight patients [8]. In other cancer types, most importantly breast cancer, 10 
however, inferior outcome has been linked to increased BMI [9, 10]. The obesity 11 
paradox seems not to hold true for patients with primary brain tumors. One study 12 
found no association with survival [11], others report a dismal prognosis for obese 13 
patients with glioma [12, 13].  14 
In a retrospective study evaluating 624 lung cancer patients with brain metastases, 15 
underweight (BMI<18.5 kg/m2) was identified as an independent negative prognostic 16 
factor [14], however, no contemporary data are available for other tumor entities. 17 
Furthermore, it is unclear whether weight loss is associated with outcome. In the 18 
present retrospective cohort analysis, we evaluate an association of the BMI at 19 
diagnosis of brain metastasis as well as weight loss during the course of disease 20 
with outcome in brain metastasis patients and derive potential implications for clinical 21 
management. 22 
 23 
2. Patients and Methods 24 
 25 
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Patients were identified by review of the electronic chart system of the University 1 
Hospital Zurich (USZ) using the search term “brain metastasis”. Data were obtained 2 
by authors AL and BG, quality of data was verified by author FW during regular joint 3 
meetings for data review, plausibility checks and random controls. Between 2004 4 
and 2016, 811 patients with the diagnosis of brain metastasis were identified. 5 
Information on body weight four weeks around the time of diagnosis of brain 6 
metastasis was available for 703 patients, of these, 553 patients (78.7%) were 7 
followed up until death. Of the remaining patients, 33 patients (4.7%) were alive at a 8 
median follow-up of 31.0 months, and 117 patients (16.6%) were lost to follow-up at 9 
a median follow-up of 12 months. Time from diagnosis of the primary tumor was 10 
determined by the original histology report. This study was approved by the Cantonal 11 
Ethics Committee Zurich (KEK-ZH-Nr. 2018-00192). Consent was obtained 12 
according to local regulations. The patient selection path is demonstrated in Figure 1 13 
(CONSORT chart). 14 
 15 
BMI was calculated as follows: BMI=weight/(height)2. Furthermore, body weight was 16 
assessed 6 months after the diagnosis of brain metastasis, an information that was 17 
available for 173 of 703 patients. The primary variables of interest were BMI, 18 
vascular comorbidities (including ischemic stroke, subdural hematoma, deep venous 19 
thrombosis, myocardial infarction, peripheral arterial occlusive disease, pulmonary 20 
embolism, multiple vascular diseases and other extracranial thrombosis), steroid 21 
intake at the time of diagnosis and survival. Overweight was graded according to the 22 
WHO criteria (underweight: BMI<18.5 kg/m2; normal weight: BMI 18.5-24.9 kg/m2; 23 
pre-adipositas: BMI 25.0-29.9 kg/m2; adipositas grade I: BMI 30.0–34.9 kg/m2; 24 
adipositas grade II: BMI 35.0–39.9 kg/m2; adipositas grade III / adipositas permagna: 25 
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BMI≥40.0 kg/m2). Pre-adipositas and adipositas grades I-III (BMI≥25.0) were 1 
grouped together and termed overweight for selected analyses. Information on 2 
comorbidities such as diabetes (available for 520 of 703 patients) or arterial 3 
hypertension (available for 660 of 703 patients) or vascular risk factors such as 4 
smoking were extracted from the medical reports or electronic chart. Pack years 5 
(PY) were determined for assessment of smoking as documented in the electronic 6 
chart. Individuals with ongoing nicotine consumption and more than 1 PY were rated 7 
as smokers. If nicotine consumption was stopped more than 10 years before the 8 
diagnosis of brain metastasis, patients were rated as non-smokers. Alcohol 9 
consumption was calculated in grams per day according to documented amount of 10 
alcoholic beverages in the electronic chart. A regular daily alcohol consume of more 11 
than 20 g/d was rated as abuse, according to the guidelines of the Swiss Federeal 12 
Alcohol Commission (EKAL) https://www.bag.admin.ch/bag/de/home/das-13 
bag/organisation/ausserparlamentarische-kommissionen/eidgenoessische-14 
kommission-fuer-alkoholfragen-ekal.html. If abuse was reported, but stopped at the 15 
time of diagnosis of brain metastasis, it was named as “former abuse”. A HbA1c 16 
value > 6.5% (if available) or prior diagnosis documented in the electronic chart were 17 
rated as diabetes mellitus. Tumor entities were confirmed by pathology reports from 18 
biopsy of the primary tumor or brain metastasis tissue in patients undergoing surgery 19 
or both. Graded prognostic assessment scores (GPA) were calculated from age, 20 
presence of extracranial metastases, KPS and number of brain metastases, 21 
representing the most conserved confounders of survival [3]. 22 
 23 
Survival times between brain metastasis diagnosis and death were determined from 24 
the electronic chart. Median overall survival (OS) was estimated using the Kaplan-25 
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Meier method. Follow-up was documented in the electronic chart, for some patients, 1 
additional follow-up information was obtained from the Cancer Registry Zurich and 2 
Zug (http://www.en.krebsregister.usz.ch).  3 
 4 
Statistical analysis was performed by IBM SPSS statistics ®, Version 23 (IBM Co., 5 
Armonk, NY, USA) and GraphPad Prism software, version 7.0 (La Jolla, CA, USA). 6 
The Kruskal-Wallis test was used for grouped analysis of unpaired data. We 7 
assessed correlations of adipositas grades or weight categories with patient 8 
characteristics using Pearson’s correlation coefficient. The Log-Rank test was used 9 
for assessment of survival differences between groups. Furthermore, a Cox 10 
Regression model was applied to identify independent predictors of outcome, with 11 
follow-up in months as time scale and items of the GPA score along with 12 
dexamethasone intake as possible confounders. Subjects with missing information 13 
were not included in multivariate analysis. Significance levels for two-sided p-values 14 
were set at p<0.05 for significant and p<0.01 for highly significant results. The 15 
datasets generated during and/or analysed during the current study are available 16 
from the corresponding author upon reasonable request. 17 
 18 
3. Results 19 
3.1. Patient database screening and characteristics 20 
Information on BMI from 2 weeks before to 2 weeks after diagnosis of brain 21 
metastasis by CT or MR imaging of the brain was available for 703 patients, 108 22 
patients were omitted from further evaluation. Patient characteristics are summarized 23 
in Table 1. We assessed correlations of adipositas grades or weight categories with 24 
patient characteristics. The items of the GPA score [3] that have been previously 25 
shown to be associated with survival of brain metastasis patients were confirmed in 26 
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our cohort (age: p=0.005; number of brain metastases p=0.0004; absence/presence 1 
of extracranial metastases p=0.011; KPS p=0.001, all Log-Rank test, data not 2 
shown). We found no correlation of BMI with age (n=687; r=0.055, p=0.148, 3 
Pearson’s Correlation, data not shown) or adipositas grades with age (n=684; 4 
p=0.213, Kruskal-Wallis test, Figure S1A) or adipositas grades with time from 5 
diagnosis of the primary tumor (n=214; p=0.291, Kruskal-Wallis test, data not 6 
shown). We also found no association of adipositas grades with steroid intake at the 7 
time of diagnosis of brain metastasis (n=552; p=0.475, Chi-Square test, data not 8 
shown). Between adipositas grades and KPS, there was evenly no association 9 
(n=630; p=0.061, Kruskal-Wallis test, Figure S1B). The median number of brain 10 
metastases was insignificantly lower in patients with overweight (medianbrain 11 
metastasis=1) compared to underweight (medianbrain metastasis=2) or normal weight 12 
(medianbrain metastasis=2) (n=683; p=0.142, Kruskal-Wallis test, Figure S1C). 13 
We furthermore found no association between adipositas grades and primary tumors 14 
(n=684; p=0.305, Chi-Square test, Figure S1D), fraction of operated patients (n=681; 15 
p=0.634, Chi-Square test, Figure S1E) or presence of extracranial metastases 16 
(n=525; p=0.727, Chi-Square test, Figure S1F). The fraction of patients pretreated 17 
with chemotherapy was similar between WHO adipositas grades (p=0.346, Chi-18 
Square test, data not shown) or weight categories (p=0.753, Chi-Square test, data 19 
not shown). We assessed WHO adipositas grades and treatment strategies for 20 
patients with the first diagnosis of BM between 2004-2010 versus 2011-2016 as well. 21 
There was no difference in terms of distribution of WHO adipositas weight grades 22 
(p=0.87, Table S1). However, we observed a significant change in treatment 23 
paradigms between the time period from 2004-2010 and 2011-2016: the rate of 24 
operated patients was higher for the years from 2004-2010 (94% vs. 63%) whereas 25 
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the rate of patients treated with radiotherapy (85% vs. 92%) or chemotherapy (41% 1 
vs. 55%) was lower (Table S1). Overall surval did not change between study periods 2 
(Table S1). 3 
There was an association between sex and adipositas grades (n=703, p=0.015, Chi-4 
Square test, data not shown) and weight categories (n=703, p=0.014, Chi Square-5 
test, Figure 2A). Post-hoc comparison revealed that the percentage of patients with 6 
overweight compared to those with normal weight was higher in the group of males 7 
than in females (p=0.003, Chi Square-test, Figure 2A). There was no difference 8 
between genders concerning the percentage of patients with underweight compared 9 
to those with overweight(p=0.248, Chi-Square test, Figure 2A). 10 
Median weight at the time of diagnosis of brain metastasis was 70.0 kg (95% CI 11 
69.0-71.0) and decreased to 68.0 kg (95% CI 64.0-70.0) after 6 months (Figure S2). 12 
Furthermore, we assessed relative weight change by division of weight values from 6 13 
months after the diagnosis of brain metastasis versus time of diagnosis. Median 14 
relative weight after 6 months was 0.95, which is equivalent to a median weight loss 15 
of 5% (95% CI 3.3 – 6.5%). A relative weight loss of 10% or above was observed in 16 
10 of 173 patients (5.8%). 17 
 18 
3.2. Associated comorbidities 19 
Electronic chart review allowed to relate the relevant comorbidities of arterial 20 
hypertension, diabetes mellitus and history of neuro- or cardiovascular disease with 21 
adipositas and outcome. There was an association between adipositas grades and 22 
incidence of arterial hypertension (n=676, p= 0.00001, Chi-Square test). This was 23 
confirmed by post-hoc analysis by direct comparison of adipositas grades (all Chi-24 
Square test, see Figure 2B for p-values). Furthermore, there was association 25 
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between adipositas grades and diabetes mellitus (n=536; p=0.032, Chi-Square test). 1 
Post-hoc analysis by direct comparison, however, confirmed this association only for 2 
pre-adipositas patients, but numbers were low for patients with adipositas grades I-III 3 
(all Chi-Square test, see Figure 2C for p-values). Since data on smoking were limited 4 
for patients with adipositas grades II and III, we pooled all patients with a BMI > 25 5 
kg/m2 in one weight category termed overweight for further analysis. There was 6 
association between smoking (PY) and weight categories (n=585; 7 
medPY(underweight)=24.5; medPY(normal weight)=15.0; medPY(overweight)=27.5; 8 
p=0.034, Kruskal-Wallis test). Post-hoc analysis by Dunn-Bonferroni-tests confirmed 9 
a significant correlation only for the comparison of normal and overweight patients 10 
(adjusted p=0.03, Figure 2D). In contrast, we found no association of weight 11 
categories with alcohol abuse (n=625; p=0.484, Chi-Square test, data not shown). 12 
Median GPA scores of underweight patients were insignificantly lower than in 13 
patients with normal or increased weight (n=576; medGPA(underweight)=1.5; 14 
medGPA(normal weight)=2; medGPA(overweight)=2; p=0.17, Kruskal-Wallis test, data 15 
not shown). 16 
 17 
3.3 Survival analyis 18 
Median follow-up was 17.0 months for surviving patients (95% CI 12-23) and median 19 
OS was 10.0 months (95% CI 8.7–11.3) for all patients. Bodyweight was associated 20 
with outcome across the different adipositas grades (p=0.003, Log-Rank test, Figure 21 
S3). There was a significant association between survival and weight categories: 22 
patients with normal weight (OS 9 months, 95% CI 7.5 -10.5) showed better OS than 23 
underweight patients (OS 6 months, 95% CI 1.6-10.3, p=0.047, Log-Rank test), but 24 
an inferior outcome compared to those with overweight (OS 13 months, 95% CI 25 
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11.0-15.0, p=0.033 Log-Rank test, Figure 3A). A sub-analysis of lung tumors only 1 
showed a better outcome of patients with normal weight (OS 12 months, 95% CI 9.1-2 
14.9) than in those with underweight (OS 5 months, 95% CI 0.1-10.1, p=0.005, Log-3 
Rank test) and similar survival as in those with overweight (OS 15 months, 95% CI 4 
11.9-18.1, p=0.55) (Figure 3B). In patients with brain metastasis from other (non-5 
lung) tumors, there was no survival difference between patients with normal weight 6 
(OS 8 months, 95% CI 6.3.-9.7) and those with underweight (OS 10 months, 95% CI 7 
4.5-15.5; p=0.87, Log-Rank test), but an inferior survival compared to those with 8 
overweight (OS 11 months, 95% CI 7.9-14.1, p=0.02, Log-Rank test) (Figure 3C). 9 
Further subgroup analysis of primary tumors other than lung was limited by small 10 
sample sizes, however the favorable prognosis of patients with overweight was 11 
confirmed for patients with brain metastasis from melanoma (p=0.042) and other 12 
primary tumors (p=0.041), and by trend for cancer of unknown primary site (p=0.070) 13 
(Figure S4). 14 
We also evaluated an association of weight loss after 6 months with overall survival. 15 
Patients with a weight loss of greater than the median of 5% showed an inferior 16 
outcome (weight loss >5%: 14.0 months, 95% CI 11.9-16.1; weight loss <5%: 22.0 17 
months, 95% CI 19.2-24.8; patients with an OS < 6 months were excluded from 18 
analysis) (Figure 3D). 19 
We also assessed survival upon stratification for the vascular risk factors that were 20 
associated with weight. We found hypertension to be associated with survival (no 21 
arterial hypertension OS 12 months, 95% CI 10.1-13.9 versus arterial hypertension 22 
OS 9 months, 95% CI 8.1 -12.1, p=0.021, Log-Rank test) (Figure 3E). For diabetes 23 
mellitus, there was an according trend (no diabetes OS 12 months, 95% CI 10.3-24 
13.7, diabetes OS 6 months, 95% CI 3.9 -8.1, p=0.0895, Log-Rank test) (Figure 3F).  25 
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We tested underweight together with the items of the GPA score, the gold standard 1 
for prognostic assessment in brain metastasis patients and thus the most conserved 2 
confounders of survival, in a multivariate Cox Regression model. Here, younger age 3 
categories compared with older age (HR 0.68, 95% CI 0.53 – 0.88), lower KPS 4 
compared with high KPS (HR 0.66, 95% CI 0.51-0.86), low number of brain 5 
metastases compared with multiple brain metastases (HR 0.5, 95%CI 0.39 – 0.64) 6 
and absence compared with presence of extracranial metastases (HR 0.78, 95% CI 7 
0.65- 0.95) at the time of diagnosis were associated with good outcome, whereas 8 
underweight (BMI<18.5 kg/m2) compared to normal weight or overweight was 9 
independently associated with inferior survival (HR 1.4, 95% CI 1.01 – 1.94) (Table 10 
2). Dexamethasone intake at the time of diagnosis of brain metastasis was not 11 
associated with outcome (HR 0.78, 95% CI 0.51 – 1.01). In the group of patients with 12 
survival above 6 months, a relative weight loss of 5% or more since diagnosis of 13 
brain metastasis was an independent predictor of poor outcome (HR 1.7, 95% CI 14 
1.16 – 2.42), but not the items of the GPA score (Table S2). 15 
 16 
4. Discussion 17 
The paradigm that obesity is per se associated with enhanced comorbidities and 18 
thus inferior survival has been challenged in recent years. Several studies including 19 
some studies on cardiovascular and oncological diseases have shown an 20 
unexpectedly superior outcome of obese patients. This has been referred to as the 21 
“obesity paradox” [4-7]. The underlying mechanism of the obesity paradox has 22 
remained unclear. Overweight has been confirmed as a risk factor for cardiovascular 23 
comorbidities such as diabetes mellitus or arterial hypertension in the last decades 24 
and was thus thought to be associated with inferior survival [15, 16]. In contrast, 25 
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recent reports describe a beneficial outcome of obese patients for coronary heart 1 
disease [17] or stroke [18]. However, available data is inconsistent since some 2 
subsequent investigations failed to confirm these findings, e.g., for stroke [17-19]. 3 
The cardiovascular risk profile of patients from our cohort confirmed a significantly 4 
higher incidence of cardiovascular risk factors such as arterial hypertension and 5 
diabetes mellitus in overweight patients (Figure 2B,C). Arterial hypertension, but not 6 
diabetes mellitus, was also associated with an inferior outcome, indicating that 7 
comorbidities shape the course of disease even in brain metastasis patients who are 8 
commonly considered to experience short survival (Figure 3E,F). 9 
Tumor cachexia is frequent in patients with metastatic cancer, and substantial 10 
evidence has shown cachexia to be associated with unfavorable outcome [4-8]. The 11 
latter has been shown recently for patients with brain metastasis from lung cancer 12 
[14]. While we confirm these findings, we demonstrate that this observation might not 13 
hold true for patients from other tumor entities: OS was significantly lower in lung 14 
cancer patients with cachexia (Figure 3B), but there was no such difference in 15 
patients from other tumor entities (Figure 3C). Conversely, overweight was 16 
associated with superior OS in patients with brain metastasis from other cancer than 17 
lung cancer (Figure 3C), but not from lung cancer (Figure 3B). Moreover, weight loss 18 
after 6 months above the median of 5% was associated with an inferior outcome in 19 
our cohort (Figure 3D). 20 
Why obese brain metastasis patients show a superior outcome remains unclear. 21 
Fast progressing and thus consuming tumors might be associated with cachexia, but 22 
we found no pattern of primary tumors being associated with certain adipositas 23 
grades (Figure S1D). Since cachexia might be a result of end stage disease, we 24 
assessed for possible bias from preselection of heavily pretreated patients. However, 25 
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neither the rate of patients pretreated with chemotherapy nor the time from cancer 1 
diagnosis to first detection of brain metastasis differed by weight categories. 2 
 3 
The observation that weight loss is associated with inferior outcome in patients with 4 
brain metastasis, is at odds with the fact that therapeutic approaches based on 5 
specific nutritional regimens, e.g., the ketogenic diet, which might be associated with 6 
reduced body weight, are in the focus of interest of cancer patients and physicians, 7 
despite insufficient data from controlled trials [20, 21]. Our database did not allow 8 
follow-up on dietary measures, which is a limitation of this study. Since such diets 9 
may result in significant weight loss, our findings underscore the need to consider 10 
such approaches with caution [20]. Conversely, treatment of tumor cachexia by 11 
specific nutrition management might help to improve outcome of brain metastasis 12 
patients, in particular from lung cancer, and might be a rewarding objective for future 13 
clinical studies. 14 
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Figures and tables 1 
Figure 1: (CONSORT) chart. The consort chart shows the selection path for 2 
patients to be included in this study. The upper part documents the preselection 3 
process to identify all brain metastasis patients, the lower part shows further 4 
assessments and subgroup analyses. 5 
 6 
Figure 2: Association of weight and vascular risk factors. A. The number of 7 
patients (x-axis) and respective sex are shown for each weight category as bar plots 8 
(black bars: underweight, dark grey bars: normal weight, light grey: overweight 9 
patients). Statistical evaluation was done by Chi-Square test, comparison between 10 
groups as indicated by brackets. B,C. Adipositas grades are shown for patients with 11 
and without arterial hypertension (B) or with and without diabetes mellitus (C) as 12 
stacked columns. Grey bars represent patients with, and black bars patients without, 13 
a diagnosis of arterial hypertension (B) or diabetes mellitus (C). Statistical evaluation 14 
was done by the Chi-square test, groups were compared as marked with brackets, 15 
p-values as indicated below. D. Smoking in PY (y-axis) is shown for each weight 16 
category (x-axis) as whisker box-plots. Boxes represent the interquartile range and 17 
whiskers the 95% CI, medians are shown as a line. Statistical evaluation was done 18 
by Kruskal-Wallis test, p values are indicated with brackets. 19 
 20 
Figure 3: Weight and survival. A-C. Kaplan-Meier survival curves are shown for 21 
different weight categories, with the y-axis marking percentage of survival and the x-22 
axis time in months. A. Survival in all brain metastasis patients is shown for 23 
individuals with underweight (dotted line), normal weight (straight line) and 24 
overweight (dashed line). Differences between groups were assessed as marked 25 
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with brackets using the Log-Rank test, p-values annotated. Similar curves are shown 1 
for subgroups with brain metastasis originating from lung cancer (B) or other 2 
primaries (C). D. The curve in (D) shows survival of patients with relative weight loss 3 
below (dotted line) or above the median of 5% (straight line). E, F. Survival curves 4 
are shown for brain metastasis patients with (dotted line) or without (straight line) the 5 
diagnosis of arterial hypertension (E) or diabetes mellitus (F). Head lines above each 6 
graph indicates the respective group of patients which was investigated. 7 
 8 
Table 1: Characteristics of brain metastasis patients. The upper part shows 9 
general characteristics including sex, age, BMI, KPS and incidence of primary 10 
tumors. The middle and lower part show information on incidence of cardiovascular 11 
risk factors. 12 
 13 
Table 2: Multivariate analysis including underweight as candidate prognostic 14 
factor. The results of multivariate testing of candidate prognostic factors are shown, 15 
which were calculated employing a Cox Hazard model. The first column depicts the 16 
respective candidate factor, the second one the two-sided p-values, the third column 17 
the respective Hazard ratios following 95% CI in the fourth and fifth column. 18 
 19 
Supplementary Material 20 
Figure S1: Association of weight and patients characteristics. A-C. Age (A), 21 
KPS (B) and number of brain metastases (C) (y-axis) are shown for each WHO 22 
adipositas grade (x-axis) (A,B) or per weight category (C) as whisker box-plots. 23 
Boxes represent the interquartile range and Whiskers 95% CI, medians are shown 24 
as broad, bold lines. Statistical evaluation was done by Kruskal-Wallis test, p values 25 
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are indicated with brackets. In C, post-hoc testing by Dunn-Bonferroni-tests is shown 1 
with p-values for subgroups as indicated by brackets. D-F. Adipositas grades are 2 
shown for each tumor entity (D), operated vs. non-operated individuals (E) and 3 
absence versus presence of extracranial metastases as stacked columns (F). 4 
 5 
Figure S2: Evolution of weight change. Weight in kg (y-axis) is shown for 6 
assessment at the time of diagnosis of brain metastasis and 6 months later (x-axis) 7 
as Whisker box-plots. Boxes represent the interquartile range and Whiskers 95% CI, 8 
medians are shown as broad, bold lines. Statistical evaluation was done by Wilcoxon 9 
test for paired samples, p values are indicated with brackets. 10 
 11 
Figure S3: Adipositas grades and survival. A. The Kaplan-Meier curve shows 12 
survial for different WHO adipositas grades (see legend for color code), with the y-13 
axis marking percentage of survival and the x-axis time in months. B. OS including 14 
95% CI is annotated for all adipositas grades. 15 
 16 
Figure S4: Other tumor types and survival. A-E. The Kaplan-Meier curve shows 17 
survial for different subgroups of primary tumors other than lung cancer, including 18 
cancer of unknown primary site (A), gastrointestinal cancer (B), breast cancer (C), 19 
melanoma (D) and other primary tumors (E). Legends indicate different weight 20 
categories according to color code, with the y-axis marking percentage of survival 21 
and the x-axis time in months. F. OS including 95% CI is annotated for all primary 22 
tumors other than lung-cancer as a table (CUP = cancer of unknown primary site). 23 
 24 
 25 
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Table S1: Characteristics of brain metastasis patients during different periods 1 
of the study. The first column shows the respective item which was assessed, the 2 
second column results for all patients, the third column results for the first half of the 3 
study period, the fourth column for the second half of the stud period and the last 4 
column results of statistical testing (all Chi-square test). 5 
 6 
Table S2: Multivariate analysis including weight loss after 6 months as 7 
candidate prognostic factor. The results of multivariate testing of candidate 8 
prognostic factors 6 months after diagnosis of BM are shown, which were calculated 9 
employing a Cox Hazard model. The first column depicts the respective candidate 10 
factor, the second one the two-sided p-values, the third column the respective 11 










- Vascular risk profile, comorbidities and 
  association with BMI
- Survival analysis including subgroups
(number of individuals as indicated, 










































































































































































































































































































All primary tumors Lung cancer
Non-lung cancer All primary tumors

















































































































































































































































































































WHO adipositas grades OS, months (95%CI)
underweight (BMI<18.5) 6 (1.6-10.4)
normal (BMI 18.5-24.9) 9 (7.5.-10.5)
pre-adiopositas (BMI 25.0-29.9) 12 (8.8-15.1)
adipositas grade I (BMI 30.0-34.9) 14 (9.2-18.8)
adipositas grade II (BMI 35.0-39-9) 11 (0.1-25.8)
adipositas grade III (BMI>40) 11 (0.1-31.5)
Overall 11 (9.5-12-5)



































































         OS (months)   95% CI 
CUP 
 underweight   2 0.1 - 4.3  
  normal    9 7.5 - 10.5
 overweight 18 7.1 - 28.9
 overall    9 3.4 - 14.6
Gastrointestinal cancer   
 underweight 10 0.0 - 20.5
 normal    6 1.6 - 10.4
 overweight   6 0.0 - 14.0
 overall    6 1.3 - 10.7
Breast cancer 
 underweight 20 16.0 - 24.0
 normal  17   6.0 - 28.0
 overweight 15 11.7 - 18.3
 overall  16 11.6 - 20.4
Melanoma 
 underweight   3 0.1 - 5.9
 normal    7 5.2 - 8.8
 overweight   7 4.6 - 9.4
 overall    7 5.5 - 8.5
Other primary tumors 
 underweight   2 0.0 - 11.8
 normal    6 2.5 - 9.5
 overweight 18 3.1 - 32.9
 overall    8  3.9 - 12.1
Table 1 
Sex, number  
male 373 
female 330 
Sex ratio (male/female) 1.13 
Age, median (range)  60.3 (19.3-88.3) 
Number of BM, median (range)  2 (1-64) 
BMI, median (range) 23.8 (15-51) 
Karnofsky Performance Score, median (range) 80 (20-100) 
Location of BM, number (%)  
deep brain 8 (1.1) 
cerebellum 68 (9.7 
brain stem 6 (0.9) 
frontal 115 (16.4) 
parietal 49 (7.0) 
occipital 32 (4.6) 
temporal 37 (5.3) 
other 10 (0.3) 
multiple BM 378 (53.8) 
Primary tumor, number (%)  
unknown 40 (5.7) 
lung cancer 288 (41.0) 
melanoma 126 (17.9) 
breast cancer 81 (11.5) 
renal cell carcinoma 23 (3.3) 
gastrointestinal 58 (8.3) 
other 87 (12.4) 
Alcohol, number (%)  
no abuse 480 (85.5) 
ongoing abuse 74 (10.5) 
former abuse 19 (2.9) 
no information 58 
Prior vascular event, number (%)  
none 589 (83.8) 
ischemic stroke 11 (1.6) 
subdural hematoma 1 (0.1) 
intracranial hemorrhage 1 (0.1) 
deep venous thrombosis 23 (3.3) 
myocardial infarction 15 (2.1) 
peripheral arterial occlusive disease 23 (3.3) 
pulmonary embolism 11 (1.6) 
multiple 24 (3.4) 
other 5 (0.7) 
Arterial hypertension, number (%)  
no 473 (68.0) 
yes 223 (31.7) 
incomplete file 7 
Diabetes, number (%)  
no 482 (92.9) 
yes 37 (7.1) 
no data 184 
Smoking,  number (%)  











 yes 380 (63.5) 
no data 105 
Smoking, pack years; median (range) 20 (0-150) 
Steroid intake at diagnosis of BM, number (%)  
no 61 (91.5) 
yes 579 (9.5) 
no data 63 









* The results of multivariate testing of candidate risk factors for association with survival are shown, which were calculated employing a 
Cox Hazard model. The first column depicts the respective candidate factor, the second one the two-sided p-values, the third column 
the respective Hazard Ratios following 95% CI in the fourth and fifth column. 
 
Candidate factors p= Hazard Ratio 95% CI 
Lower Upper 
Age (GPA score: >60y = 0, 50-59y=0.5 ; <50y=1) 0.0057 0.67 0.50 0.89 
Number of BM (GPA score: >3=0, 2-3=0.5, 1=1) 0.0003 0.49 0.37 0.64 
KPS (GPA score: <70% = 0, 70-80%=0.5 ; 90-100%=1) 0.0083 0.68 0.51 0.91 
Extracranial metastases (GPA score: yes=1; none=0) 0.0448 0.80 0.65 0.99 
Underweight (BMI<18.5 kg/m2) 0.0327 1.40 1.03 2.23 
Table S1 
 
 All (n=703) 2004-2010 (n=186) 2011-2016 (n=517) p= 
Adipositas grade n (%)       0.871 
underweight (BMI<18.5) 53 (7.5) 14 (7.0) 39 (7.8)  
normal (BMI 18.5-24.9) 380 (54.1) 101 (55.2) 279 (53.8)  
pre-adiopositas (BMI 25.0-29.9) 183 (26.0) 49 (26.4) 134 (25.6)  
adipositas grade I (BMI 30.0-34.9) 64 (9.1) 16 (8.0) 48 (9.6)  
adipositas grade II (BMI 35.0-39-9) 13 (1.8) 2 (2.0) 11 (1.8)  
adipositas grade III (BMI>40) 10 (1.4) 4 (1.5) 6 (1.4)  
 
 Surgery n (%) 
No 203 (28.9) 11 (5.9) 192 (37.1) <0.001 
Yes 500 (71.1) 175 (94.1) 325 (62.9)  
  
Radiotherapy n (%)        
No 69 (10.2) 26 (15.0) 43 (8.5) 0.015 
Yes 608 (89.8) 147 (85.0) 461 (91.5)  
Incomplete file 26  
  
Chemotherapy after diagnosis of BM n (%)        
no 344 (49.1) 109 (59.2) 235 (45.5) 0.001 
yes 356 (50.9) 75 (40.8) 281 (54.5)  
Incomplete file 3  
        
Overall survival, months (95% CI) 10 (8.7-11.3) 10.0 (7.3-12.7) 10.0 (8.7-11.5)  









* The results of multivariate testing of candidate risk factors for association with survival are shown, which were calculated employing a 
Cox Hazard model. The first column depicts the respective candidate factor, the second one the two-sided p-values, the third column 
the respective Hazard Ratios following 95% CI in the fourth and fifth column. 
 
Candidate factors p= Hazard Ratio 95% CI 
Lower Upper 
Age (GPA score: >60y = 0, 50-59y=0.5 ; <50y=1) 0.167 0.713 0.44 1.15 
Number of BM (GPA score: >3=0, 2-3=0.5, 1=1) 0.316 0.768 0.46 1.29 
KPS (GPA score: <70% = 0, 70-80%=0.5 ; 90-100%=1) 0.629 0.880 0.53 1.48 
Extracranial metastases (GPA score: yes=1; none=0) 0.522 0.888 0.62 1.28 
Weight loss (more than 5% within the first 6 months) 0.006 1.676 1.16 2.42 
Epilepsy in patients with brain metastasis 
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Table 1. Patient characteristics stratified for absence versus presence of BTRE+. 
  





Sex, m/f 427/372 298/275 129/97 0.284a 
Age, median (range)  60.5 (20.5-90.1) 60.9 (20.5-90.1) 58.4 (26.6-84.9) 0.004*b 
Number of BM, median (range)  2 (1-64) 2 (1-64) 1 (1-20) 0.095b 
KPS, median (range) 80 (20-100) 80 (30-100) 80 (20-100) 0.829b 
Primary tumor, n (%)   
unknown 45 (5.6) 34 (75.6) 11 (24.4) 0.556 a 
lung cancer 332 (41.6) 225 (67.8) 107 (32.2) 0.037 a 
melanoma 143 (17.9) 105 (73.4) 38 (26.6) 0.616 a 
breast cancer 93 (11.6) 76 (81.7) 17 (18.3) 0.023 a 
renal cell cancer 28 (3.5) 20 (71.4) 8 (28.6) 0.973 a 
gastrointestinal cancer 63 (7.9) 46 (73.0) 17 (270) 0.811 a 
other 95 (11.9) 66 (68.8) 30 (31.3) 0.784a 
Alcohol, n (%)  
no abuse 624 (85.5) 444 (71.5) 180 (28.5) Ref. 
ongoing abuse (> 30g/d) 84 (11.5) 54 (64.3) 30 (35.7) 0.420a 
former abuse 22 (3.0) 16 (72.7) 6 (27.3) 0.812a 
no information 81  
First seizure, type, n (%)  
focal seizures (intact awareness) 83 (36.7) 
focal seizures (impaired awareness) 21 (9.3) 
generalized tonic-clonic (onset unknown) 92 (40.7) 
generalized, non-motor (onset unknown) 8 (3.5) 
status epilepticus 12 (5.3) 
incomplete file 10 
AED prophylaxis, n (%)   
no primary prophylaxis 573 (72.7) 395 (68.9) 178 (31.1) Ref. 
primary prophylaxis 150 (19.0) 104 (69.3) 46 (30.7) 0.582 a 
perioperative prophylaxis 65 (8.2)  
Localization of BM, n (%)  
deep brain 8 (2.6) 8 (100.0) 0 (0.0) 0.942a 
cerebellum 64 (21.1) 57 (89.1) 7 (10.9) 0.899a 
brain stem 6 (2.0) 5 (83.3) 1 (16.7) 0.798a 
frontal 110 (36.2) 62 (56.4) 48 (43.6) 0.094a 
parietal 49 (16.1) 32 (65.3) 17 (34.7) 0.809a 
occipital 27 (8.9) 16 (59.3) 11 (40.7) 0.886a 
temporal 39 (12.8) 32 (82.1) 7 (17.9) 0.121a 
supratentorial 226 (74.3) 142 (62.8) 84 (37.2) <0.001 
infratentorial 78 (25.7) 70 (89.7) 8 (10.3) Ref. 
missing information 61  
multiple BM  434  
Surgery, n (%)  
  
 
no surgery 242 (30.3) 193 (79.8) 49 (20.2) Ref. 
one or more surgeries 557 (69.7) 380 (68.2) 177 (31.8) 0.001a 
file incomplete 2  
Extent of resection of supratentorial 
single BM 
  
no surgery 28 (17.0)  
biopsy 1 (0.6)  
partial resection 87 (52.7)  
gross total resection 49 (29.3)  
no post-operative MRI 61  
Treatments administered after BM 
diagnosis in non-operated patients, 
n (%)  
  
no chemotherapy or RT 9 (3.8)  
RT only 103 (43.1)  
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chemotherapy only 5 (2.1)  
chemotherapy and radiotherapy 122 (51.0)  
incomplete file 4  
no radiotherapy  14 (5.9) 12 (85.7) 2 (20.7) Ref. 
radiotherapy  224 (94.1) 177 (79.0) 47 (21.0) 0.553a 
no chemotherapy 114 (47.1) 91 (79.8) 23 (20.2) Ref. 
chemotherapy 128 (52.9) 101 (78.9) 27 (21.1) 0.860a 
Treatments administered after surgery  
of BM, n (%) 
  
no chemotherapy or RT 58 (11.0)  
RT only 216 (41.1)  
chemotherapy only 12 (2.3)  
chemotherapy and radiotherapy 239 (45.5)  
incomplete file 32  
no radiotherapy  72 (13.6) 58 (80.6) 14 (19.4) Ref. 
radiotherapy  456 (86.4) 300 (65.8) 156 (34.2) 0.013 
no chemotherapy 296 (53.5) 218 (73.6) 78 (26.4) Ref. 
chemotherapy 257 (46.5) 158 (61.5) 99 (38.5) 0.002 
 
+ The results of database screening are shown. The first column depicts the respective 
characteristics item, with main items in bold letters and sub-characters in normal letters. The 
second column shows overall values for all patients, values as indicated. Percentages for sub-
items reflect their fraction compared to the whole entity of a main item. The third and fourth 
columns show the fraction of patients without and with seizures, marked with italic letters. 
Percentages refer to the fraction of patients with or without seizures for each item. RT indicates 
radiotherapy of the brain. 
 
*Results of statistical testing, indicating p-values. Significant values are highlighted with bold 
letters, the respective statistical test is indicated with superscript letters: a = Chi square test; b = 
Mann-Whitney U test; Ref. = group of patients that served as a reference. 
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+ The first column depicts the respective characteristics item, with main items in bold letters and 














Sex, m/f 291/266 247/224 44/42 0.827a 
Age, median (range)  61.9 (22.9-90.1) 62.2 (22.9-90.1) 60.6 (31.7-84.9) 0.073
b 
Number of BMs, median (range)  1 (1-36) 1 (1-36) 1 (1-20) 0.854
b 
KPS, % (range) 80 (20-100) 80 (30-100) 80 (20-100) 0.988 




unknown 39 (7.4) 35 (89.7) 4 (10.3) 0.342 a 
lung cancer 224 (40.2) 183 (81.7) 41 (18.3) 0.085 a 
melanoma 90 (16.2) 76 (84.4) 14 (15.6) 0.956 a 
breast cancer 64 (11.5) 56 (87.5) 8 (12.5) 0.307 a 
renal cell cancer 23 (4.1) 22 (95.7) 1 (4.3) 0.130 a 
gastrointestinal cancer 53 (7.0) 47 (88.7) 6 (11.3) 0.540 a 
other 64 (11.5) 52 (81.3) 12 (18.8) 0.585 a 
Number of BM, n (%)     
single BM 239 (43.2) 203 (84.9) 36 (15.1) Ref. 
multiple BM 314 (56.8) 265 (84.4) 49 (15.6) 0.861 a 
incomplete file 1  
Localization of BM (supratentorial 
versus infratentorial), n (%) 
    
single supratentorial BM  198 (75.9) 160 (80.8)) 38 (19.2) 0.012 
single infratentorial BM 66 (25.0) 62 (93.9) 4 (6.1) Ref. 
     
Localization of single supratentorial 
BM, n (%) 
   0.020a 
frontal 94 (47.5) 80 (85.1) 14 (14.9) 0.144
a 
parietal 44 (22.2) 34 (77.3) 10 (22.7) 0.500a 
occipital 25 (12.6) 16 (64.0) 9(36.0) 0.027
a 
temporal 33 (17.2) 30 (88.2) 4 (11.8) 0.022a 
Depth of single supratentorial BM, n 
(%) 
    
cortical or sub-cortical 175 (88.8) 144 (82.3) 31 (17.7) 0.114a 
other  22 (11.2) 15 (68.2) 7 (31.8) Ref. 
Number of surgeries, n (%)    0.039 b 
one brain surgery 456 (81.9) 401 (87.9) 55 (12.1) Ref. 
two or more brain surgeries 101 (18.1) 70 (69.3) 31 (30.7) <0.001
b 
Cerebral venous thrombosis, n (%)     
no 547 (98.3) 465 (84.7)) 82 (15.3) Ref. 
yes 10 (1.7) 6 (60.0) 4 (40.0) 0.030 
Extent of resection of supratentorial 
single BM, n (%) 
   0.011 
Biopsy 2 (1.4) 1 (100.0) 0 (0) 
Ref. 
partial resection 87 (63.0) 63 (72.4) 24 (27.6) 
gross total resection 49 (35.5) 45 (91.8) 4 (8.2) 0.008 
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indicated. Percentages for sub-items reflect their fraction. The third and fourth column show the 
fraction of patients without and with seizures. Percentages refer to the fraction of patients with or 
without seizures for each item. 
 
* Results of statistical testing, indicating p-values. Significant values are highlighted with bold 
letters, the respective statistical test is indicated with superscript letters: a, Chi square test; b, 
Mann-Whitney U test, Ref. = group of patients that served as the reference. 
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+ AED used for secondary seizure prophylaxis in BM patients with BTRE are shown. The first 
column shows the respective AED, the subsequent columns depict the number of patients which 
received the respective agent as a first to fifth line of seizure prophylaxis. The second lowest line 
shows all patients with, and the lowest line all patients without, the respective line of AED 
treatment. 
AED agent 1st 2nd 3rd 4th 5th 
Valproic acid 22 9 3 0 1 
Levetiracetam 85 16 2 1 0 
Phenytoin 52 5 1 0 0 
Carbamazepine 5 7 0 0 0 
Phenobarbital 2 4 1 0 0 
Lamotrigine 2 4 2 0 0 
Benzodiazepins 23 39 8 0 0 
other 6 0 0 0 0 
 
on AED 197 84 17 1 1 
no AED 29 142 209 225 225 
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Table S2. Characteristics of non-operated BM patients.+ 
 
+ The first column shows the respective characteristics, with main items in bold letters and sub-
characters in normal letters. The second column shows overall values for all patients. Percentages 
for sub-items reflect their fractions. The third and fourth column show the fraction of patients 
 







Sex, m/f 134/107 103/88 30/19 0.359a 
Age, median (range)  56.8 (20.5-85.2) 57.0 (20.5-85.2) 55.2 (26.6-79.8) 0.182b 
KPS, median (range) 85 (20-100) 80 (40-100) 90 (20-100) 0.857b 
Number of BM, median (range) 4 (1-64) 4 (1-64) 2 (1-19) 0.013
b 
one single BM (n, %) 51 (21.3) 34 (66.7) 17 (33.3) 0.007
a 
multiple BM (n, %) 189 (78.7) 158 (83.6) 31 (16.5) Ref. 
incomplete file 2  
Primary tumor, n (%)  
  
0.816a 
unknown 6 (2.5) 5 (83.3) 1 (16.7)  
lung cancer 108 (44.6) 89 (82.4) 19 (17.6)  
melanoma 53 (21.9) 41 (77.4) 12 (22.6)  
breast cancer 29 (12.0) 23 (79.3) 6 (20.7)  
renal cell cancer 5 (2.1) 3 (60.0) 2 (40.0)  
gastrointestinal 10 (4.1) 9 (90.0) 1 (10.0)  
other 31 (12.8) 28 (77.8) 8 (22.2)  
First seizure, type, n (%)  
  
 
focal seizures (intact awareness)  10 (21.7) 
focal seizures (impaired awareness)  11 (23.9) 
generalized tonic-clonic (onset unknown)  23 (50.0) 
generalized, non-motor (onset unknown)  0 
status epilepticus)  2 (4.4) 
incomplete file)  3 
Localization of BM (supratentorial versus 




single supratentorial BM) 28 (70.0) 18 (64.3) 10 (35.7)  
single infratentorial BM)  12 (30.0) 8 (66.7) 4 (33.3)  
Localization of BM (lobe), n (%)     
cerebellum 9 (22.5) 6 (66.7) 3 (33.3)  
brain stem 3 (7.5) 2 (66.7) 1 (33.3)  
frontal 16 (40.0) 10 (62.5) 6 (37.5)  
parietal 5 (12.5) 3 (60.0) 2 (40.0)  
occipital 2 (5.0) 2 (100) 0 (0.0)  
temporal 5 (12.5) 3 (60.0) 2 (40.0)  
multiple BM  202  





subcortical or cortical 26 (92.9) 16 (61.5) 10 (38.5)  
white matter  2 (7.1) 2 (100) 0 (0)  





no 153 (64.3) 129 (84.3) 24 (15.7)  
yes 85 (35.7) 61 (71.8) 24 (28.2)  
file incomplete 4  
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without and with seizures. Percentages refer to the fraction of patients with or without seizures for 
each item. 
 
*Results of statistical testing, indicating p-values. Significant values are highlighted with bold 
letters, the respective statistical test is indicated with superscript letters: a, Chi square test; b, 
Mann-Whitney U test; Ref. = group of patients that served as a reference. 
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+The results of subgroup of patients, who were operated, is shown. The first column depicts the 
respective characteristics item, with main items in bold letters and sub-items in normal letters. The 
second column shows overall values for all patients, values as indicated. Percentages for sub-
 
 













Sex, m/f 291/263 228/217 63/46 0.219a 
Age, median (range)  61.4 (22.9-90.1) 62.3 (22.9-90.1) 60.1 (31.7-84.9) 0.160
b 
KPS, median (range) 80 (20-100) 80 (30-100) 80 (20-100) 0.319b 
Number of BM, median (range)  1 (1-36) 1 (1-36) 1 (1-20) 0.433
b 
Primary tumor, n (%)  
  
0.037a 
unknown 39 (7.0) 32 (82.1) 7 (17.9) 0.895 a 
lung cancer 222 (40.1) 166 (74.8) 56 (25.2) 0.007a 
melanoma 90 (16.2) 77 (85.6) 13 (14.4) 0.159a 
breast cancer 63 (11.4) 59 (93.7) 4 (6.3) 0.005a 
renal cell cancer 23 (4.2) 18 (78.3) 5 (21.7) 0.892a 
gastrointestinal 53 (9.6) 41 (77.4) 12 (22.6) 0.740 a 
other 67 (11.6) 52 (82.1) 12 (17.9) 0.733a 
First pre-operative seizure, type,  




focal seizures (intact awareness) 48 (44.4) 
focal seizures (impaired awareness) 6 (4.6) 
generalized tonic-clonic (onset 
unknown) 
46 (42.6) 
generalized, non-motor (onset 
unknown) 
6 (5.6) 
status epilepticus 3 (2.8) 
incomplete file 3 
Number of BM (n, %) 
    
single BM 238 (43.3) 188 (79.0) 50 (21.0) Ref. 
multiple BM 312 (56.7) 254 (81.4) 58 (18.6) 0.480 a 
Incomplete file 4  
Location of BM (supratentorial 
versus infratentorial) (n, %) 
    
single supratentorial BM 199 (74.0) 150 (75.4) 49 (24.6) <0.001 
single infratentorial BM 70 (26.0) 70 (100) 0 (0) Ref. 
Localization of single 
supratentorial BM (n, %) 
   0.026a 
frontal 94 (47.7) 63 (66.3)) 32 (33.7) 0.007
a 
parietal 44 (22.3) 34 (75.6) 11 (24.4) 0.911a 
occipital 25 (12.7) 21 (84.0) 4 (16.0) 0.297a 
temporal 33 (16.8) 31 (93.9) 2 (6.1) 0.110a 
Depth of single supratentorial BM 
(n, %) 
    
subcortical or cortical 174 (88.8) 128 (73.6) 46 (26.4) 0.075a 
white matter  22 (11.2) 20 (90.9) 2 (9.1) Ref. 
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items reflect their fraction compared to the whole entity of a main item. The third and fourth column 
show the fraction of patients without and with seizures, marked with italic letters. Percentages 
refer to the fraction of patients with or without seizures for each item. 
 
*Results of statistical testing, indicating p-values. Significant values are highlighted with bold 
letters, the respective statistical test is indicated with superscript letters: a, Chi square test; b, 
Mann-Whitney U test; Ref. = group of patients that served as a reference. 
 
 
